FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 294 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Breast Cancer Vaccine Has Eliminated Cancer In Its First Human Patient December 16, 2019 Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival... March 30, 2022 Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult... December 13, 2024 En gran cantidad de casos el exito o examen experto os... August 21, 2023 Load more HOT NEWS 5-Year-Old Boy Meets Generous Stem Cell Donor Who Cured Him Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers Nurse With Terminal Breast Cancer Spends Her Days Caring For Pediatric... Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and...
